Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cefalonium is a first-generation, semi-synthetic cephalosporin antibiotic belonging to the β-lactam class. It exhibits broad-spectrum bactericidal activity against Gram-positive and some Gram-negative bacteria, including *Staphylococcus aureus* (including penicillin-resistant strains), *Streptococcus* species, *Escherichia coli*, *Klebsiella* spp., and others commonly associated with bovine mastitis. Its primary mechanism of action is inhibition of bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby interfering with the final phase of peptidoglycan synthesis and leading to cell lysis and death. Cefalonium is primarily used in veterinary medicine for routine dry cow therapy—to treat existing subclinical infections and prevent new intramammary infections during the dry period in dairy cattle.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefalonium.